Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection

Phase 2 Completed 79 enrolled University of Wisconsin, Madison Agency for Healthcare Research and Quality (AHRQ) · collab Henry Ford Hospital · collab Mayo Clinic · collab Medical College of Wisconsin · collab

RandomizedParallel-groupDouble-blindPrevention

Summary

This study evaluates the efficacy of prophylaxis with oral vancomycin for preventing recurrent Clostridium difficile Infection (CDI) in patients who have experienced at least one CDI episode in the last 180 days and are receiving antibiotics for a non CDI condition. Participants will be randomized to receive either placebo or oral vancomycin in addition to their prescribed antibiotic therapy.

Timeline

Start: 2018-05-21
Primary completion: 2023-07-06
Completion: 2023-07-06

Publications

Keating JA, Xu T, Graham MB, Ramesh M, Khanna S, Dixon J, Kates A, Haight K, Zhao J, Saddler C, Safdar N. Oral Vancomycin for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial. JAMA Netw Open. 2025 Jul 1;8(7):e2517834. doi: 10.1001/jamanetworkopen.2025.17834.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vancomycin	Other / unclassified	125 mg	Oral

Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection

Summary

Timeline

Publications

Drugs

Indications